Manuscript Topics

Our knowledge of the molecular pathogenesis of cancer has considerably increased in the last decade due to the substantial efforts made by the scientific community in the characterization of the different tumor types. Alterations such as chromosomal aberrations, mutations, changes in gene expression, epigenetic modifications, miRNAs deregulation, variations in non-coding region, among others, have been widely described in cancer. The –omics (transcriptomics, genomics, proteomics, metabolomics…) and other massive approaches have provided us with exciting signatures that may help in the clinical setting in early diagnosis, predict disease evolution and therapeutic decision. Auto-antibodies profiles also appear as attractive biomarkers. However the limited translation into the clinical practice of these findings highlights the probable gap that exists between the bench and the patient bedside. This issue invites articles that address those alterations in specific tumor types that are promising biomarkers in the early detection of the disease, prognosis of the outcomes and/or defining therapeutic responses. Manuscripts focused on the problems that hamper the rapid integration of these findings into the clinical routine and how close/far we are to the personalized medicine are also welcome.

Instruction for Authors
http://www.aimspress.com/aimsg/news/solo-detail/instructionsforauthors
Please submit your manuscript to online submission system
https://aimspress.jams.pub/